FIG. 7.

Cybr-deficient DCs prime T cells in vivo. Wild-type (WT) or Cybr^−/− BMDCs were pretreated with LPS plus IFN-γ, pulsed with OVA peptide, and analyzed for the ability to prime OVA-specific TCR transgenic T cells in vivo. OVA-pulsed BMDCs were injected into the footpads of CD45.1⁺ congenic mice. Concomitantly, CD45.2⁺ CFSE-labeled OT-II T cells were injected into the tail veins of recipient mice. Three days later, draining lymph nodes were isolated and CD45.2⁺ CD4⁺ T cells were analyzed for cytokine production by intracellular staining and for proliferation by CFSE dilution. KO, knockout.